Many believe that Market Access is all about national pricing and reimbursement approval. The truth is that now, Payers will continue to explore the value being delivered by your brand well after launch, and make decisions about continued reimbursement; removing brands from reimbursement or reducing prices if they no longer believe they are delivering value. GalbraithWight Value Confirmation services help you plan for these events, and help you develop and deliver a robust plan to gather the evidence you will need in the future to confirm the value promised is actually being delivered to patients.
Prospective Patient Outcomes & Real World Evidence Plans
Increasingly, Payers are demanding evidence post approval that your medicine actually delivers on the value promised, as they believe outcomes will be worse in a general population than in your clinical trials. Many HTA agencies now have an ongoing review process, where they will assess each medicine already approved on a 3-4 year review cycle which invariably results in a further price negotiation.
It is vital to be prepared for these events, by putting in place a robust plan to gather prospective health outcomes for your medicines so that you can demonstrate the value delivered in real-life, in a heterogenous patient population. GalbraithWight can help you develop the plan to gather real-world evidence, and use this to build a compelling story about the value your brand continues to deliver value to patients, the healthcare system and society well beyond first approval.
Early Access Programs
In the period leading up to marketing authorisation, but prior to full reimbursement approval, there may be the opportunity to provide early access to your innovative medicines for patients with significant need.
Processes vary from country to country, such as ATU in France or 648 list in Italy. GalbraithWight can help you develop an effective Early Access Program which ensures that those patients in greatest need can gain access, while at the same time building further evidence on outcomes which may support pricing and reimbursement negotiations.
What Our Clients Say
Why Partner with GalbraithWight
The global Strategic Market Access Consultancy with 20 years thought leadership partnering Pharma and Biotech Clients.
Experts in value strategy based on in-depth customer insights, creating value through clinical and HEOR evidence, achieving successful pricing, reimbursement and funding approval, brand launch and commercialisation, from discovery to loss of exclusivity.
Unparalleled expertise in building market access and commercial capabilities from foundation to expert level for global, regional and country teams, training thousands of managers from over 70 countries across five continents.
Highly expert team with extensive senior level strategic and operational international experience in major Pharma companies, who know and understand how to embed & operationalise our solutions in complex organisations and cross-functional teams, delivered on the ground throughout North and South America, Europe, Asia, Middle East and Africa.